Altered messenger RNA and protein expressions for insulin-like growth factor family members in clear cell and papillary renal cell carcinomas

International Journal of Urology

Volumn 12, Issue 1, 2005, Pages 17-28

  Cheung, Catherine ^c   Vesey, David ^a   Cotterill, Andrew ^b   Douglas, Meaghan ^c   Gobe, Glenda ^c   Nicol, David ^a,c   Johnson, David ^a,c  

^a PRINCESS ALEXANDRA HOSPITAL   (Australia)

^b MATER HOSPITAL   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Immunohistochemistry; Insulin like growth factor binding proteins; Insulin like growth factor I; Renal cell carcinoma; RT PCR

Indexed keywords

MESSENGER RNA; PROTEIN; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 4; SOMATOMEDIN BINDING PROTEIN 5; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; CLEAR CELL CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; KIDNEY DISTAL TUBULE; KIDNEY PAPILLARY CARCINOMA; KIDNEY PROXIMAL TUBULE; MALE; MULTIGENE FAMILY; ONCOCYTOMA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADENOCARCINOMA, CLEAR CELL; ADENOMA, OXYPHILIC; CARCINOMA, PAPILLARY; CARCINOMA, RENAL CELL; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEINS; INSULIN-LIKE GROWTH FACTOR I; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 14744293814     PISSN: 09198172     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2004.00993.x     Document Type: Article

References (38)

1. Kellerer M, von Eye Corleta H, Muhlhofer A et al. Insulin- and insulin-like growth-factor-I receptor tyrosine-kinase activities in human renal carcinoma. Int. J. Cancer 1995; 62: 501-507.
2. Jungwirth A, Serially AV, Pinski J, Groot K, Armatis P, Halmos G. Growth hormone-releasing hormone antagonist MZ-4-71 inhibits in vivo proliferation of Caki-I renal adenocarcinoma. Proc. Natl Acad. Sci. USA 1997; 94: 5810-13.
3. Datta K, Nambudripad R, Pal S, Zhou M, Cohen HT, Mukhopadhyay D. Inhibition of insulin-like growth factor-I-mediated cell signaling by the von Hippel-Lindau gene product in renal cancer. J. Biol. Chem. 2000; 275: 20700-20706.
4. Pekonen F, Partanen S, Rutanen EM. Binding of epidermal growth factor and insulin-like growth-factor I in renal carcinoma and adjacent normal kidney tissue. Int. J. Cancer 1989; 43: 1029-33.
5. Hintz RL, Bock S, Thorsson AV et al. Expression of the insulin like growth factor-binding protein 3 (IGFBP-3) gene is increased in human renal carcinomas. J. Urol. 1991; 146: 1160-3.
6. Johnson DW, Saunders HJ, Brew BK et al. Human renal fibroblasts regulate proximal tubule cell growth and transport via the IGF-I axis. Kidney Int. 1997; 52: 1486-96.
7. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J. Cell. Physiol. 2000; 183: 1-9.
8. Lissoni P, Barni S, Ardizzoia A et al. Clinical efficacy of cancer subcutaneous immunotherapy with interleukin-2 in relation to the pretreatment levels of tumor growth factor insulin-like growth factor-1. Tumori 1995; 81: 261-4.
9. Chomzynski P, Sacchi N. Single-step method of RNA isolation by acid guanidium thiocyanate-phenolchloroform extraction. Anal. Biochem. 1987; 162: 156-9.
10. Tobin G, Yee D, Brunner N, Rotwein P. A novel human insulin-like growth factor I messenger RNA is expressed in normal and tumor cells. Mol. Endocrinol. 1990; 4: 1914-20.
11. Quinn KA, Treston AM, Unsworth EJ et al. Insulin-like growth factor expression in human cancer cell lines. J. Biol. Chem. 1996; 271: 11477-83.
12. Bell GI, Merryweather JP, Sanchez-Pescador R et al. Sequence of a cDNA clone encoding human preproinsulin-like growth factor II. Nature 1984; 310: 775-7.
13. Ullrich A, Gray A, Tam AW et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J. 1986; 5: 2503-12.
14. Oh Y, Nagalla SR, Yamanaka Y, Kim HS, Wilson E, Rosenfeld RG. Synthesis and characterization of insulin-like growth factor-binding protein (IGFBP)-7. Recombinant human mac25 protein specifically binds IGF-I and -II. J. Biol Chem. 1996; 271: 30322-5.
15. Porcu P, Ferber A, Pietrzkowski Z et al. The growth-stimulatory effect of simian virus 40 T antigen requires the interaction of insulin-like growth factor 1 with its receptor. Mol. Cell. Biol. 1992; 12: 5069-77.
16. Tanaka T, Kondo S, Iwasa Y, Hiai H, Toyokuni S. Expression of stress-response and cell proliferation genes in renal cell carcinoma induced by oxidative stress. Am. J. Pathol. 2000; 156: 2149-57.
17. Chow WH, Gridley G, Fraumeni JF, Jarvholm B. Obesity, hypertension and the risk of kidney cancer in men. N. Engl. J. Med. 2000; 343: 1305-11.
18. Lee CT, Wu S, Gabrilovich D et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res. 1996; 56: 3038-41.
19. Halmos G, Schally AV, Varga JL, Plonowski A, Rekasi Z, Czompoly T. Human renal cell carcinoma expresses distinct binding sites for growth hormone-releasing hormone. Proc. Natl Acad. Sci. USA 2000; 97: 10555-60.
20. Long L, Navab R, Brodt P. Regulation of the Mr 72,000 type IV collagenase by the type I insulin-like growth factor receptor. Cancer Res. 1998; 58: 3243-7.
21. Hagemann T, Gunawan B, Schulz M, Fuzesi L, Binder C. mRNA expression of matrix metalloproteases and their inhibitors differs in subtypes of renal cell carcinomas. Eur. J. Cancer 2001; 37: 1839-46.
22. Akagi Y, Liu W, Zebrowski B, Xie K, Ellis LM. Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-I. Cancer Res. 1998; 58: 4008-14.
23. Skrtic S, Wallenius V, Ekberg S, Brenzel A, Gressner AM, Jansson JO. Insulin-like growth factors stimulate expression of hepatocyte growth factor but not transforming growth factor beta 1 in cultured hepatic stellate cells. Endocrinology 1997; 138: 4683-9.
24. Natali PG, Prat M, Nicotra MR et al. Overexpression of the met/HGF receptor in renal cell carcinomas. Int. J. Cancer 1996; 69: 212-17.
25. Freeman MR, Washecka R, Chung LW. Aberrant expression of epidermal growth factor receptor and HER-2 (erbB-2) messenger RNAs in human renal cancers. Cancer Res. 1989; 49: 6221-5.
26. Gomella LG, Sargent ER, Wade TP, Anglard P, Linehan WM, Kasid A. Expression of transforming growth factor alpha in normal human adult kidney and enhanced expression of transforming growth factors alpha and beta 1 in renal cell carcinoma. Cancer Res. 1989; 49: 6972-5.
27. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta 1 on programmed cell death through a p53- and IGF-independent mechanism. J. Biol. Chem. 1997; 272: 12181-8.
28. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J. Biol. Chem. 1995; 270: 13589-92.
29. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J. Biol. Chem. 1998; 273: 18347-52.
30. Kaicer E, Blat C, Imbenotte J et al. IGF binding protein-3 secreted by the prostate adenocarcinoma cells (PC-3): differential effect on PC-3 and normal prostate cell growth. Growth Regul. 1993; 3: 180-9.
31. Martin JL, Coverley JA, Pattison ST, Baxter RC. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 1995; 136: 1219-26.
32. Hoeflich A, Yang Y, Huber S et al. Expression of IGFBP-2-3, and -4 mRNA during differentiation of Caco-2 colon epithelial cells. Am. J. Physiol. Endocrinol. Metab. 1996; 34: E922-31.
33. Singh P, Dai B, Dhruva B, Widen SG. Episomal expression of sense and antisense insulin-like growth factor (IGF)-binding protein-4 complementary DNA alters the mitogenic response of a human colon cancer cell line (HT-29) by mechanisms that are independent of and dependent upon IGF-I. Cancer Res. 1994; 54: 6563-70.
34. Perks CM, Bowen S, Gill ZP, Newcomb PV, Holly JMP. Differential IGF-independent effects of insulin-like growth factor binding proteins (1-6) on apoptosis of breast epithelial cells. J. Cell. Biochem. 1999; 75: 652-64.
35. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J. Endocrinol. 2002; 172: 423-40.
36. Ewton DZ, Coolican SA, Mohan S, Chernausek SD, Florini JR. Modulation of insulin-like growth factor actions in L6A1 myoblasts by insulin-like growth factor binding protein (IGFBP)-4 and IGFBP-5: a dual role for IGFBP-5. J. Cell. Physiol. 1998; 177: 47-57.
37. Slootweg MC, Ohlsson C, Salles JP, Devries CP, Netelenbos JC. Insulin-like growth-factor binding protein-2 and protein-3 stimulate growth-hormone receptor-binding and mitogenesis in rat osteosarcoma cells. Endocrinology 1995; 136: 4210-17.
38. Hoeflich A, Fettscher O, Lahm H et al. Overexpression of insulin-like growth factor-binding protein-2 results in increased tumorigenic potential in Y-1 adrenocortical tumor cells. Cancer Res. 2000; 60: 834-8.